Literature DB >> 25879096

First rank symptoms for schizophrenia.

Karla Soares-Weiser1, Nicola Maayan, Hanna Bergman, Clare Davenport, Amanda J Kirkham, Sarah Grabowski, Clive E Adams.   

Abstract

BACKGROUND: Early and accurate diagnosis and treatment of schizophrenia may have long-term advantages for the patient; the longer psychosis goes untreated the more severe the repercussions for relapse and recovery. If the correct diagnosis is not schizophrenia, but another psychotic disorder with some symptoms similar to schizophrenia, appropriate treatment might be delayed, with possible severe repercussions for the person involved and their family. There is widespread uncertainty about the diagnostic accuracy of First Rank Symptoms (FRS); we examined whether they are a useful diagnostic tool to differentiate schizophrenia from other psychotic disorders.
OBJECTIVES: To determine the diagnostic accuracy of one or multiple FRS for diagnosing schizophrenia, verified by clinical history and examination by a qualified professional (e.g. psychiatrists, nurses, social workers), with or without the use of operational criteria and checklists, in people thought to have non-organic psychotic symptoms. SEARCH
METHODS: We conducted searches in MEDLINE, EMBASE, and PsycInfo using OvidSP in April, June, July 2011 and December 2012. We also searched MEDION in December 2013. SELECTION CRITERIA: We selected studies that consecutively enrolled or randomly selected adults and adolescents with symptoms of psychosis, and assessed the diagnostic accuracy of FRS for schizophrenia compared to history and clinical examination performed by a qualified professional, which may or may not involve the use of symptom checklists or based on operational criteria such as ICD and DSM. DATA COLLECTION AND ANALYSIS: Two review authors independently screened all references for inclusion. Risk of bias in included studies were assessed using the QUADAS-2 instrument. We recorded the number of true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN) for constructing a 2 x 2 table for each study or derived 2 x 2 data from reported summary statistics such as sensitivity, specificity, and/or likelihood ratios. MAIN
RESULTS: We included 21 studies with a total of 6253 participants (5515 were included in the analysis). Studies were conducted from 1974 to 2011, with 80% of the studies conducted in the 1970's, 1980's or 1990's. Most studies did not report study methods sufficiently and many had high applicability concerns. In 20 studies, FRS differentiated schizophrenia from all other diagnoses with a sensitivity of 57% (50.4% to 63.3%), and a specificity of 81.4% (74% to 87.1%) In seven studies, FRS differentiated schizophrenia from non-psychotic mental health disorders with a sensitivity of 61.8% (51.7% to 71%) and a specificity of 94.1% (88% to 97.2%). In sixteen studies, FRS differentiated schizophrenia from other types of psychosis with a sensitivity of 58% (50.3% to 65.3%) and a specificity of 74.7% (65.2% to 82.3%). AUTHORS'
CONCLUSIONS: The synthesis of old studies of limited quality in this review indicates that FRS correctly identifies people with schizophrenia 75% to 95% of the time. The use of FRS to diagnose schizophrenia in triage will incorrectly diagnose around five to 19 people in every 100 who have FRS as having schizophrenia and specialists will not agree with this diagnosis. These people will still merit specialist assessment and help due to the severity of disturbance in their behaviour and mental state. Again, with a sensitivity of FRS of 60%, reliance on FRS to diagnose schizophrenia in triage will not correctly diagnose around 40% of people that specialists will consider to have schizophrenia. Some of these people may experience a delay in getting appropriate treatment. Others, whom specialists will consider to have schizophrenia, could be prematurely discharged from care, if triage relies on the presence of FRS to diagnose schizophrenia. Empathetic, considerate use of FRS as a diagnostic aid - with known limitations - should avoid a good proportion of these errors.We hope that newer tests - to be included in future Cochrane reviews - will show better results. However, symptoms of first rank can still be helpful where newer tests are not available - a situation which applies to the initial screening of most people with suspected schizophrenia. FRS remain a simple, quick and useful clinical indicator for an illness of enormous clinical variability.

Entities:  

Mesh:

Year:  2015        PMID: 25879096      PMCID: PMC7079421          DOI: 10.1002/14651858.CD010653.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  131 in total

1.  The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.

Authors:  Jonathan J Deeks; Petra Macaskill; Les Irwig
Journal:  J Clin Epidemiol       Date:  2005-09       Impact factor: 6.437

2.  First-rank symptoms and Bleuler's basic symptoms. New results in applying the polydiagnostic approach.

Authors:  P Berner; H Katschnig; G Lenz
Journal:  Psychopathology       Date:  1986       Impact factor: 1.944

3.  The polydiagnostic interview: a structured interview for the polydiagnostic classification of psychiatric patients.

Authors:  M Philipp; W Maier
Journal:  Psychopathology       Date:  1986       Impact factor: 1.944

4.  Problem of diagnosis in postmortem brain studies of schizophrenia.

Authors:  C Hill; N Keks; S Roberts; K Opeskin; B Dean; A MacKinnon; D Copolov
Journal:  Am J Psychiatry       Date:  1996-04       Impact factor: 18.112

5.  Psychotic symptom patterns and the diagnosis of schizophrenia.

Authors:  M Mauri; C Borri; D Giannotti; S Zambotto; G B Cassano; H S Akiskal
Journal:  Psychopathology       Date:  1992       Impact factor: 1.944

6.  Concurrent validity of the OPCRIT diagnostic system. Comparison of OPCRIT diagnoses with consensus best-estimate lifetime diagnoses.

Authors:  M Craddock; P Asherson; M J Owen; J Williams; P McGuffin; A E Farmer
Journal:  Br J Psychiatry       Date:  1996-07       Impact factor: 9.319

7.  First rank symptoms and diagnosis of schizophrenia in developing countries.

Authors:  S H Ahmed; S Naeem
Journal:  Psychopathology       Date:  1984       Impact factor: 1.944

8.  Schneider's first rank symptoms of schizophrenia in Kenyan patients.

Authors:  D M Ndetei; A Singh
Journal:  Acta Psychiatr Scand       Date:  1983-03       Impact factor: 6.392

9.  The diagnostic stability of ICD-10 psychiatric diagnoses in clinical practice.

Authors:  T Daradkeh; O El-Rufaie; Y Younis; R Ghubash
Journal:  Eur Psychiatry       Date:  1997       Impact factor: 5.361

10.  The Cantabria first episode schizophrenia study: a summary of general findings.

Authors:  J L Vázquez-Barquero; M J Cuesta Nuñez; M de la Varga; S Herrera Castanedo; L Gaite; A Arenal
Journal:  Acta Psychiatr Scand       Date:  1995-03       Impact factor: 6.392

View more
  14 in total

Review 1.  Canadian Guidelines for the Assessment and Diagnosis of Patients with Schizophrenia Spectrum and Other Psychotic Disorders.

Authors:  Donald Addington; Sabina Abidi; Iliana Garcia-Ortega; William G Honer; Zahinoor Ismail
Journal:  Can J Psychiatry       Date:  2017-07-21       Impact factor: 4.356

Review 2.  First Rank Symptoms for Schizophrenia (Cochrane Diagnostic Test Accuracy Review).

Authors:  Karla Soares-Weiser; Nicola Maayan; Hanna Bergman; Clare Davenport; Amanda J Kirkham; Sarah Grabowski; Clive E Adams
Journal:  Schizophr Bull       Date:  2015-05-04       Impact factor: 9.306

Review 3.  Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis.

Authors:  Lena Palaniyappan; Nicola Maayan; Hanna Bergman; Clare Davenport; Clive E Adams; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2015-08-07

Review 4.  Are Essential Trace Elements Effective in Modulation of Mental Disorders? Update and Perspectives.

Authors:  Mehran Shayganfard
Journal:  Biol Trace Elem Res       Date:  2021-04-27       Impact factor: 3.738

5.  Exploration of the cortical pathophysiology underlying visual disturbances in schizophrenia comorbid with depressive disorder-An evidence from mouse model.

Authors:  Jian Liu; Lidan Zheng; Tao Fang; Ranli Li; Xiaoyan Ma; Yun Sun; Lina Wang; Hongjun Tian; Deguo Jiang; Chuanjun Zhuo
Journal:  Brain Behav       Date:  2021-03-17       Impact factor: 2.708

Review 6.  Cannabis and Psychosis Through the Lens of DSM-5.

Authors:  Nathan T Pearson; James H Berry
Journal:  Int J Environ Res Public Health       Date:  2019-10-28       Impact factor: 3.390

7.  Schneider's first-rank symptoms and treatment outcome.

Authors:  Raffael Massuda
Journal:  Braz J Psychiatry       Date:  2020 Jan-Feb       Impact factor: 2.697

8.  Clinical characterization of brief psychotic disorders triggered by the COVID-19 pandemic: a multicenter observational study.

Authors:  María José Valdés-Florido; Álvaro López-Díaz; Fernanda Jazmín Palermo-Zeballos; Nathalia Garrido-Torres; Paula Álvarez-Gil; Iván Martínez-Molina; Victoria Eugenia Martín-Gil; Elena Ruiz-Ruiz; Macarena Mota-Molina; María Paz Algarín-Moriana; Antonio Hipólito Guzmán-Del Castillo; Ángela Ruiz-Arcos; Rafael Gómez-Coronado; Sara Galiano-Rus; Alfonso Rosa-Ruiz; Juan Luis Prados-Ojeda; Luis Gutierrez-Rojas; Benedicto Crespo-Facorro; Miguel Ruiz-Veguilla
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-04-03       Impact factor: 5.270

9.  Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study.

Authors:  Michael Leo Birnbaum; Prathamesh Param Kulkarni; Anna Van Meter; Victor Chen; Asra F Rizvi; Elizabeth Arenare; Munmun De Choudhury; John M Kane
Journal:  JMIR Ment Health       Date:  2020-09-01

10.  Adding evidence of the effects of treatments into relevant Wikipedia pages: a randomised trial.

Authors:  Clive E Adams; Alan A Montgomery; Tony Aburrow; Sophie Bloomfield; Paul M Briley; Ebun Carew; Suravi Chatterjee-Woolman; Ghalia Feddah; Johannes Friedel; Josh Gibbard; Euan Haynes; Mohsin Hussein; Mahesh Jayaram; Samuel Naylor; Luke Perry; Lena Schmidt; Umer Siddique; Ayla Serena Tabaksert; Douglas Taylor; Aarti Velani; Douglas White; Jun Xia
Journal:  BMJ Open       Date:  2020-02-20       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.